Prolonged-release dosage forms of ferroportin inhibitors

Abstract

Described are novel prolonged-release pharmaceutical solid oral dosage forms comprising a ferroportin inhibitor such as vamifeport as the active pharmaceutical ingredient (API), processes for manufacturing the novel prolonged-release dosage forms, and their use in the prophylaxis and treatment of diseases treatable by ferroportin inhibitors, such as hereditary haemochromatosis, including prophylactic and therapeutic methods of treatment comprising orally administering the dosage forms to a subject in need thereof.

Images